OTC drugs of abuse test labeling with SAMHSA drug standards urged at public hearing.
This article was originally published in The Tan Sheet
Executive Summary
OTC DRUGS OF ABUSE TEST LABELING WITH SAMHSA LIMITATIONS SUGGESTED by Benjamin Gerson, MD, American Society of Clinical Pathologists, at a June 19 public hearing to solicit public comment on FDA's proposed rule to downclassify collection devices for OTC drugs of abuse tests from Class III to Class I. Labeling should "clearly and explicitly" state what drugs the system will and will not test based on the standards of the Substance Abuse & Mental Health Services Administration, Gerson said.